^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway.

Published date:
05/16/2018
Excerpt:
All pts with PR had tumors harboring FGFR fusions; one with urothelial transitional cell carcinoma (FGFR3-TACC3 F17T8) and the other with squamous cell carcinoma of cervix (FGFR3-TACC3 F17T11)
DOI:
10.1200/JCO.2018.36.15_suppl.2503
Trial ID:
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W

Excerpt:
One patient with cervical cancer harboring an FGFR3-TACC3.F17T8 gene fusion underwent prior surgery and radiation therapy and received 2 months of cisplatin approximately 8.5 years before enrollment….Clinical Characteristics and Genomic Aberrations of the Patients Who Achieved PR (n = 4) and SD for > 6 months (n = 3)
DOI:
10.1200/JCO.19.02630